Delcath SystemsDCTH
Recorded

Delcath Systems 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration25 minParticipants10

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good morning, ladies and gentlemen. Welcome to the Delcath Systems Third Quarter 2026 Earnings Conference Call. At this time, all lines are in listen-only mode. Following the presentation, we will conduct a question-and-answer session. If at any time during this call you require immediate assistance, please press star 0 for the operator. This call is being recorded on November 9, 2026. I would now like to turn the conference over to Mr. David Hoffman, Delcath General Counsel.

David HoffmanGeneral Counsel

Please go ahead. Thank you, and welcome to Delcath Systems Third Quarter 2026 Earnings Call.

David HoffmanGeneral Counsel

With me on the call are Gerard Michel, Chief Executive Officer, Sandra Pennell, Chief Financial Officer, Kevin Muir, Chief Commercial Officer, Vojo Vukovic, Chief Medical Officer, and Martha Rook, Chief Operating Officer. This statement is made pursuant to the Safe Harbor for forward-looking statements described in the Private Securities Litigation Reform Act of 1995. All statements made on this call, with the exception of historical facts, may be considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Although the company believes that expectations and assumptions reflected in these forward-looking statements are reasonable, it makes no assurance that such expectations will prove to have been correct.

David HoffmanGeneral Counsel

Actual results may differ in a material manner from those expressed or implied in forward-looking statements due to various risks and uncertainties. For a discussion of such risks and uncertainties, please see the risk factors detailed in the company's annual report on Form 10-K, quarterly reports on Form 10-Q, and other reports that the company files from time to time with the Securities and Exchange Commission. Any forward-looking statements included in this call are made only as of the date of this call. We do not undertake any obligation to update or supplement any forward-looking statements to reflect subsequent knowledge, events, or circumstances. We will also discuss adjusted EBITDA, a non-GAAP financial measure. This measure should not be considered a substitute for GAAP results. The reconciliation to net income is included in our earnings release.

David HoffmanGeneral Counsel

The third quarter 2026 earnings release is available in the Investors section of our website, along with additional details on our financial results and our latest SEC filings. We encourage you to review those materials. A recording of today's call will also be available on our website. Now, I'll turn the call over to Gerard Michel.

Gerard MichelCEO

Gerard, please proceed. Thank you, David, and good morning.

Gerard MichelCEO

Delcath Systems' record third quarter of $35.1 million in revenue, up 71% from the third quarter in 2025, reflects the growing adoption of HEPZATO KIT and the hard work of both the Delcath Systems and physician treatment teams. Just as importantly, we are delivering positive operating cash flow, which gives us the flexibility to support investment in both the treatment networks and ongoing research that will expand the platform. The growth in profitability was driven by strong new patient starts for the quarter at approximately 0.6 new patient starts per site per month. We now have 33 active treatment centers in the U.S. Since our last update, we have added the University of Nebraska and AdventHealth.

Gerard MichelCEO

Two additional new centers have patients scheduled this month, and we expect at least one more activation before year-end, which would bring us to at least 36 centers by year-end. The addition of AdventHealth is especially meaningful given its scale as one of the nation's largest integrated health systems, with more than 50 hospitals, over 2,000 care sites, and roughly 4 million unique patients served each year, providing a robust platform for referral volume and systemwide utilization of HEPZATO. Our focus remains on both expanding the network and increasing utilization at existing centers through referral relationships, community physician education, and better coordination across the patient pathway. Combination treatment with systemic therapy is increasingly becoming the norm. Most physicians view the two approaches as complementary rather than mutually exclusive. CHOPIN has provided an important foundation for this treatment strategy, and independent real-world experience continues to inform patient selection and sequencing strategy.

Gerard MichelCEO

In the third quarter, the 1,000th commercial HEPZATO treatment in the United States took place, which reflects the broadening acceptance of the therapy across a growing number of centers. In addition, University Hospital Southampton delivered their 500th CHEMOSAT procedure, led by Dr. Sachin Modi. This illustrates how, once a center gains experience and sees results, the therapy tends to become firmly incorporated as an important component of standard of care. On the clinical development side, the phase II colorectal trial continues to enroll at a pace that supports an interim analysis in the middle of next year. As we've discussed in prior calls, enrollment in the breast cancer trial has been slower than initially anticipated. We are not yet in a position to provide guidance on the timing of an interim analysis.

Gerard MichelCEO

However, the first patient was dosed in July at the European Institute of Oncology in Milan, and we now have multiple sites recruiting patients in Europe and the U.S., and we continue to work with sites to support enrollment. We are also expanding our pipeline with a planned IND submission for cholangiocarcinoma in early 2027, and pending FDA agreement. Completion of an ongoing preclinical development of an oxaliplatin-based PHP program by mid-2027 to support a subsequent IND. Both clinical programs have substantial strategic significance. The cholangiocarcinoma trial has broad support in the medical community based on both clinical development experience with CHEMOSAT in Europe and the very high unmet need. Delcath Systems is exploring the oxaliplatin-based PHP product because physicians are already highly familiar and comfortable with oxaliplatin as a standard backbone agent in colorectal and other GI cancer treatments.

Gerard MichelCEO

By delivering high-dose oxaliplatin regionally through the Hepatic Delivery System and reducing systemic exposure, we may be able to incorporate it in the standard FOLFOX regime in patients with liver-dominant cancers without meaningfully increasing toxicity, particularly cumulative neuropathy. From a biology standpoint, many oncologists view oxaliplatin as a better match to colorectal liver metastases, and therefore may be more comfortable using oxaliplatin-based PHP treatment in a first or second-line setting versus a melphalan-based product. We will provide updates on these two programs as they reach regulatory and operational milestones in 2027. With that, I'll turn the call over to Sandra.

Sandra PennellCFO

Thank you, Gerard. For third quarter of 2026, total revenue was $35.1 million compared with $20.6 million in the third quarter of 2025. HEPZATO KIT revenue was $32.7 million compared to $19.3 million in the prior year third quarter. This represents a HEPZATO volume increase of 19% from the prior quarter and 72% year-over-year. CHEMOSAT revenue was $2.4 million compared with $1.3 million in the prior year third quarter. Gross margin was 89% for the quarter compared with 87% in the third quarter of 2025. Research and development expense was $11 million compared with $8 million in the prior year quarter. The increase primarily reflects additional clinical headcount and increased clinical trial activity. Selling, general, and administrative expense was $13.1 million compared with $10.3 million in the prior year quarter. This increase reflects our continued investment in commercial expansion.

Sandra PennellCFO

Net income was $7 million compared with $0.8 million in the third quarter of 2025. On a non-GAAP basis, adjusted EBITDA was $11.5 million compared with $5.3 million in the prior year quarter. These results demonstrate the operating leverage in our commercial model. At the same time, quarterly profitability may vary as we continue to invest in treatment network expansion and clinical development. We ended the quarter with $104.3 million in cash and investments and no debt. Cash generated from operations was $8.2 million for the quarter compared with $4.8 million in the prior year quarter. Turning to our 2026 outlook, we are raising our full-year total revenue guidance to a range of $115 million-$117 million. We expect at least a 41% HEPZATO KIT volume growth over 2025.

Sandra PennellCFO

Our guidance reflects $25.8 million-$27.8 million total revenue in the fourth quarter of 2026, a year-on-year growth of approximately 25%-34%. We also expect full-year gross margin of 87%-89% and positive adjusted EBITDA. Thank you for joining us today. I'll now turn the call back to the operator to open the lines for questions. Operator, we are opening the line back for questions.

Operator

Thank you. Ladies and gentlemen, we will now conduct a question-and-answer session. If you would like to ask a question, please press star one on your telephone keypad. A confirmation tone will indicate your line is in the queue. You may press star two if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. One moment, please, while we poll for questions. The first question comes from Marie Thibault with BTIG.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day